Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Caliway Biopharmaceuticals Co. L (6919.TW)
New Taipei City, TW
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
44.36M
est: 43.00M (+3.2%)
|
37.98M
est: 38.00M (-0.1%)
|
6.03B
6.03B – 6.03B
+15,773.7% YoY
|
11.73B
11.73B – 11.73B
+94.5% YoY
|
| EBITDA |
-686.50M
est: -43.00M (-1,496.5%)
|
-683.54M
est: -38.00M (-1,698.8%)
|
-6.03B
-6.03B – -6.03B
-15,773.7% YoY
|
-11.73B
-11.73B – -11.73B
-94.5% YoY
|
| EBIT |
-715.96M
est: -43.00M (-1,565.0%)
|
-706.09M
est: -38.00M (-1,758.1%)
|
-6.03B
-6.03B – -6.03B
-15,773.7% YoY
|
-11.73B
-11.73B – -11.73B
-94.5% YoY
|
| Net Income |
-587.85M
est: -728.36M (+19.3%)
|
-351.35M
est: -648.11M (+45.8%)
|
-1.00B
-1.00B – -1.00B
-54.8% YoY
|
8.29B
8.29B – 8.29B
+926.2% YoY
|
| SGA |
97.63M
est: 110.22M (-11.4%)
|
83.07M
est: 97.40M (-14.7%)
|
15.46B
15.46B – 15.46B
+15,773.7% YoY
|
30.07B
30.07B – 30.07B
+94.5% YoY
|
| EPS |
-0.41
est: -0.47 (+13.1%)
|
-0.23
est: -0.42 (+45.2%)
|
-0.65
-0.65 – -0.65
-54.8% YoY
|
5.37
5.37 – 5.37
+926.2% YoY
|
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Taiwan ETF EWT | 0.37% | 39.13M | 0.59% |
| 2 | Franklin FTSE Taiwan ETF FLTW | 0.16% | 4.87M | 0.19% |
| 3 | iShares MSCI EM Consumer Growth UCITS ETF CEMG.L | 0.15% | 63.4K | 0.60% |
| 4 | iShares MSCI Taiwan UCITS ETF IDTW.L | 0.15% | 2.31M | 0.74% |
| 5 | Franklin FTSE Taiwan UCITS ETF FLXT.MI | 0.15% | 961.8K | 0.19% |
| 6 | HSBC ETFs Public Limited Company - HSBC MSCI Taiwan UCITS ETF HTWN.L | 0.14% | 151.1K | 0.50% |
| 7 | Xtrackers MSCI Taiwan UCITS ETF 1C XMTD.L | 0.14% | 667.4K | 0.65% |
| 8 | Amundi MSCI Emerging Ex China ESG Selection UCITS ETF DR (C) EMXU.L | 0.07% | 762.5K | 0.35% |
| 9 | iShares MSCI Emerging Markets Asia ETF EEMA | 0.05% | 452.1K | 0.49% |
| 10 | iShares ESG Advanced MSCI EM ETF EMXF | 0.05% | 80.7K | 0.16% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6919.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
